Comparative Assessment of the Preventive Use of Intra-Aortic Baloon Counterpulsation and Levosimendan in Patients with Coronary Heart Disease and Low Left Ventricular Ejection Fraction
https://doi.org/10.15360/1813-9779-2012-1-41
Abstract
The aim of our study was to compare the efficiency of the use of intraaortic balloon counterpulsation (IABP) and levosi-mendan in patients with low left ventricular ejection fraction operated on under cardiopulmonary bypass. The study included 90 patients who were randomized into three groups according to the strategy of hemodynamic support. Group A patients received IABP 24 hours before surgery. In group B, preventive IABP was combined with intraoperative levosimendan infusion. Group C patients received intraoperative levosimendan infusion only. Hemodynamics, the markers of myocardial damage and heart failure, postoperative complications and length of hospital stay were observed. The patients treated with lev-osimendan had a more stable hemodynamic profile. Troponin I level was significantly lower in Group C six hours after cardiopulmonary bypass than that in group A. Length of stay in intensive care was significantly lower in Group C. The pre-operative concentration of BNP (>360 pg/ml) is a predictor of inotropic support in the postoperative period. The results of our study indicate that the use of levosimendan in high-risk patients is effective and shows the results comparable with those of intra-aortic balloon counterpulsation.
References
1. Soliman Hamad M. A., van Straten A. H., van Zundert A. A. et al.
2. Чернявский А. М, Марченко А. В., Чармадов М. В. и соавт.Динамика диастолической и систолической функции левого желудочка у больных ишемической болезнью сердца с выраженной постинфарктной левожелудочковой дисфункцией после хирургического лечения. Патология кровообращения и кардиохирургия 2010; 1: 56—59.
3. Cohen M, Urban P., Christenson J. T. et al.Intra-aortic balloon counter-pulsation in US and non-US centers: results of the Benchmark Registry. Eur. Heart J. 2003; 24 (19): 1763—1770.
4. Ломиворотов В. В., Калинин Р. А., Сидельников С. Г. и соавт.Влияние внутриаортальной баллонной контрпульсации на состояние центральной гемодинамики и кислородтранспортной функции системы кровообращения у больных ишемической болезнью сердца с низкой (<30%) фракцией выброса левого желудочка при операциях реваскуляризации миокарда. Патология кровообращения и кардиохирургия 2008; 2: 39—43.
5. Marra C., De Santo L. S., Amarelli C. et al.Coronary artery bypass grafting in patients with severe left ventricular dysfunction: a prospective randomized study on the timing of perioperative intraaortic balloon pump support. Int. J. Artif. Organs 2002; 25 (2): 141—146.
6. Ramnarine I. R., Grayson A. D., Dihmis W. C. et al.Timing of intra-aor-tic balloon pump support and 1-year survival. Eur. J. Cardiothorac. Surg. 2005; 27 (5): 887—892.
7. Maccioli G. A., Lucas W. J., Norfleet E. A. et al.The intra-aortic balloon pump: a review. J. Cardiothorac. Anesth. 1988; 2 (3): 365—373.
8. Riaz W., Shahbaz A., Sami W., KhanJ. S.Early vascular complications of intraaortic balloon counterpulsation in patients undergoing open heart surgery. J. Ayub. Coll. Abbottabad. 2008; 20 (2): 80—84.
9. Hasenfuss G., Pieske B., Castell M. et al.Influence of the novel inotrop-ic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98 (20): 2141—2147.
10. Labriola C., Siro-Brigiani M., Carrata F. et al.Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int. J. Clin. Pharmacol. Ther. 2004; 42 (4): 204—211.
11. ЛомиворотовВ. В., БобошкоВ. А., ЧернявскийА. М. исоавт.Сравнительная оценка профилактического использования внутриаор-тальной баллонной контрпульсации и левосимендана у пациентов ИБС с низкой фракцией выброса левого желудочка. Патология кровообращения и кардиохирургия 2011; 2: 53—59.
12. Pfeiffer S., Frisch P., Weyand M. et al.The use of preoperative intra-aor-tic balloon pump in open heart surgery. J. Cardiovasc. Surg. (Torino) 2005; 46 (1): 55—60.
13. MeharwalZ. S., Trehan N.Vascular complications of intra-aortic balloon insertion in patients undergoing coronary revascularization: analysis of 911 cases. Eur. J. Cardiothorac. Surg. 2002; 21 (4): 741—747.
14. Maharaj R., Metaxa V.Levosimendan and mortality after coronary revascularization: a meta-analysis of randomized controlled trials. Crit. Care 2011; 15 (3): R140.
15. Lilleberg J., Nieminen M. S., AkkilaJ. et al.Effects of a new calcium sen-sitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur. Heart J. 1998; 19 (4): 660—668.
16. Alvarez J., Taboada M., Rodriguez J. et al.Hemodynamic effects of levosimendan following cardiac surgery. Rev. Esp. Anestesiol. Reanim. 2005; 52 (7): 389—394.
17. De Hert S. G., Lorsomradee S., vanden Eede H. et al.A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction. J. Cardiothorac. Vasc. Anesth. 2008; 22 (5): 699—705.
18. Christenson J. T., Badel P., Simonet F. et al.Preoperative intraaortic balloon pump enhances cardiac performance and improves the outcome of redo CABG. Ann. Thorac. Surg. 1997; 64 (5): 1237—1244.
19. Dyub A. M., Whitlock R. P., AbouzahrL. L., Cina C. S.Preoperative intra-aor-tic balloon pump in patients undergoing coronary bypass surgery: a systematic review and meta-analysis. J. Cardiac Surg. 2008; 23 (1): 79—86.
20. Slawsky M. T., Colucci W. S., Gottlieb S. S. 6t al.Acute hemodynamic and clinical effects oflevosimendanin patients with severe heart failure. Circulation 2000; 102 (18): 2222—2227.
21. An Geene Y., van Swieten H. A., Noyez L.Cardiac troponin I levels after cardiac surgery as predictor for in-hospital mortality. Interact. Cardiovasc. Thorac. Surg. 2010; 10 (3): 413—416.
22. du Toit E. F., Genis A., Opie L. H. et al.A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimen-dan in the isolated guinea pig heart. Br. J. Pharmacol. 2008; 154 (1): 41—50.
23. Mcbride B. F., White C. M.Levosimendan: implications for clinicians. J. Clin. Pharmacol. 2003; 43 (10): 1071—1081.
24. Ruskoaho H.Cardiac hormones as diagnostic tools in heart failure. Endocr. rev. 2003; 24 (3): 341—356.
25. Hutfless R., Kazanegra R., Madani M. et al.Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J. Am. Coll. Cardiol. 2004; 43 (10): 1873—1879.
26. Козлов И. А., Харламова И. Е., Кричевский Л. А.Предоперационный уровень натрийуретических пептидов в-типа и результаты клини-ко-функционального обследования кардиохирургических больных. Общая реаниматология 2009; V (3): 24—28.
Review
For citations:
Boboshko V.A., Lomivorotov V.V., Chernyavsky A.M., Kornilov I.A., Knyazkova L.G. Comparative Assessment of the Preventive Use of Intra-Aortic Baloon Counterpulsation and Levosimendan in Patients with Coronary Heart Disease and Low Left Ventricular Ejection Fraction. General Reanimatology. 2012;8(1):41. (In Russ.) https://doi.org/10.15360/1813-9779-2012-1-41
Views:
1236
Email this article 